BioAtla (BCAB) Stock Price, News & Analysis

Company Overview

BioAtla, Inc. was a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company used its Conditionally Active Biologics (CAB) platform to design antibody-based medicines intended to become active primarily within the tumor microenvironment, with the goal of improving treatment effectiveness while limiting effects on healthy tissue.

BioAtla’s investigational pipeline included antibody-drug conjugates and immune-modulating therapies. Its lead programs included mecbotamab vedotin, an antibody-drug conjugate designed to target AXL, and ozuriftamab vedotin, an investigational therapy directed at ROR2. The company also evaluated other CAB-based candidates for potential use in solid tumors and hematologic malignancies.

BioAtla was founded in 2007 and was headquartered in San Diego, California. Its programs were developed for potential treatment of cancers in the United States and international markets through clinical research and collaborations. The company later announced a strategic review and substantial reductions to its operations, and its publicly traded activities were subsequently wound down.

Key Stats

• Today's Range: $1.86 to $2.00
• 50-Day Range: $1.08 to $3.14
• 52-Week Range: $1.07 to $71.50
• Volume: 5,224 shs
• Average Volume: 49,685 shs
• Market Capitalization: $3.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $200.00
• Consensus Rating: Hold

BioAtla Stock Analysis - MarketRank™

BioAtla scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

BioAtla has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

BioAtla has a consensus price target of $200.00, representing about 9,900.0% upside from its current price of $2.00.

Amount of Analyst Coverage

BioAtla has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioAtla is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioAtla is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BCAB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioAtla does not currently pay a dividend.

Dividend Growth

BioAtla does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioAtla insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.34% of the stock of BioAtla is held by insiders.

Percentage Held by Institutions

77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/05/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCAB
• CIK: 1826892
• Web: www.bioatla.com
• Phone: 858-558-0708
• Fax: N/A
• Employees: 60
• Year Founded: 2007

Price Target and Rating

• Average Price Target for BioAtla: $200.00
• High Price Target: $200.00
• Low Price Target: $200.00
• Potential Upside/Downside: +9,900.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($25.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59.61 million
• Net Margins: N/A
• Pretax Margin: -370.05%
• Return on Equity: N/A
• Return on Assets: -289.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.20
• Quick Ratio: 0.20

Sales & Book Value

• Annual Sales: $8.50 million
• Price / Sales: 0.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($28.51) per share
• Price / Book: -0.07

Miscellaneous

• Outstanding Shares: 1,666,000
• Free Float: 1,510,000
• Market Cap: $3.33 million
• Optionable: No Data
• Beta: 0.64